Akela Pharma Inc.
3333 Côte Vertu
Suite 710
St-Laurent
Quebec
H4R 2N1
Canada
Tel: 514-315-3330
Fax: 514-315-3325
Website: http://www.labinc.ca/
45 articles about Akela Pharma Inc.
-
Akela Pharma Inc. Announces Completion of Asset Foreclosure on Formulation Technologies, LLC
3/14/2013
-
CEO Rudy Emmelot Resigns From Akela Pharma Inc.
3/11/2013
-
Akela Pharma Inc. Announces Notice of Asset Foreclosure on Formulation Technologies, LLC
2/25/2013
-
Akela Pharma Inc. Delists From the Toronto Stock Exchange
12/10/2012
-
Akela Pharma Inc. Announces Voluntary Delisting From the Toronto Stock Exchange
12/3/2012
-
Akela Pharma Inc. Announces Board of Director Transition
9/24/2012
-
Akela Pharma Inc. Reports Results for the Three and Six Months Ended June 30, 2012
8/15/2012
-
Akela Pharma Inc. Announces Board of Director Transition
7/18/2012
-
Akela Pharma Inc. Reports Financial Results for the Three Months Ended March 31, 2012
5/16/2012
-
Akela Pharma Inc. Reports Financial Results for the Year Ended 2011
4/2/2012
-
Akela Pharma Inc. Reports Results for the Three and Nine Months Ended September 30, 2011
11/16/2011
-
Akela Pharma Inc. Reports results for the three and six months ended June 30, 2011
8/16/2011
-
Akela Pharma Inc. and PharmaForm LLC Expand Drug Formulation and Manufacturing Capabilities
11/4/2009
-
Akela Pharma Inc. to Cut Staff by 33 Percent, to Close Sites
9/3/2009
-
Akela Pharma Inc. Announces New CEO
9/2/2009
-
Akela Pharma Inc. Appoints New Board of Directors
6/26/2009
-
Akela Pharma Inc. and Nventa Biopharmaceuticals Corporation Announce Closing of Merger
5/22/2009
-
Akela Pharma Inc. to Buy Nventa Biopharmaceuticals Corporation in Stock Deal Worth C $1.4 Million
3/27/2009
-
Akela Pharma Inc. to Cut Costs to Sustain Long-Term Viability of the Company
2/9/2009
-
Akela Pharma Inc. Announces Achievement of Third Fentanyl TAIFUN(R) Phase 3 Study Related Milestone
1/13/2009